Owkin, a NYC-based company which builds machine learning technologies and infrastructure to enable medical research, received a funding round of undisclosed amount.
The round was led by F-Prime Capital and Eight Roads Ventures, joined by GV, Cathay Innovation and NJF Capital. In conjunction with the funding, Alex Pasteur, Partner at F-Prime Capital, joined Owkin’s board.
The company intends to use the funds to expand its partner network worldwide and deploy its flagship machine learning platform to augment medical research.
Founded in 2016 by Thomas Clozel M.D., CEO, Owkin builds machine learning technologies to enable medical and scientific discoveries. These algorithms support drug development by predicting treatment outcomes and disease evolution. It interprets the model’s features and variables to discover multimodal biomarkers and works with clinicians to biologically validate these new biomarkers. Owkin’s network enables federated learning for the healthcare industry, allowing researchers to train predictive models on heterogeneous real-world data while preserving patient privacy.
The predictive models are implemented in clinical trials through analysis enrichment, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification.
Owkin has also appointed F-Prime Capital/Eight Roads Entrepreneur-in-Residence Parker Moss as Chief Business Officer.